On Oct. 21, 2025, BriaCell Therapeutics Corp. announced the addition of Dartmouth Cancer Center, Cedars‑Sinai Medical Center, and Winship Cancer Institute of Emory University to its pivotal Phase 3 study (NCT06072612).
The expansion now includes Mayo Clinic, Los Angeles Cancer Network, Smilow Cancer Hospital at Yale New Haven, Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology/Oncology Associates, New York Cancer and Bood Specialists, and Texas Oncology‑Baylor Charles A. Sammons Cancer Center.
The addition of these high‑profile academic and community centers increases patient enrollment capacity, accelerates recruitment, and positions BriaCell to meet its target of 144 patient events for interim analysis. The company expects to report top‑line data in the first half of 2026, a milestone that could drive regulatory approval and market access for its lead candidate Bria‑IMT.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.